The instrument demonstrated excellent discriminantability among LC patients with varying courses of disease. At a basic level, physicians can judge differentstages of disease according to the results of the LCPROM. This will save time relative to the method offull reliance on laboratory indicators.In a word, the LC-PROM instrument we developedfills a gap in patient-reported clinical outcomes of LC,and lacks the deficiencies seen with existing liver diseasePRO tools. It also has the capacity to discriminate disease course, and to evaluate clinical effects and HRQOLaccurately; therefore, it will provide valuable data to newdrug development for LC.